Primary,adaptive,and acquired resistance to cancer immunotherapy. Sharma P,Hu-Lieskovan S,Wargo JA,et al. Cell . 2017Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168: 707 - 723...
Figure 1. Clinical Scenarios of Primary, Adaptive, and Acquired Resistance to Immunotherapy (A) Patient’s tumor is resistant to immunotherapy with no active immune response. (B) Patient’s tumor is resistant to immunotherapy; active anti-tumor immune response, but turned off by checkpoints or ...
Despite unprecedented clinical activity across multiple types of cancer with programmed death 1 (PD-1)/ligand-1 (PD-L1) blockade therapy, the majority of patients do not respond (primary resistance) or develop resistance after initial tumor regression (acquired resistance)1. This is due, at least...
resulting in significant clinical efficacy and lasting responses. However, these therapies do not work for a large proportion of patients initially, which is called primary resistance. And more frustrating is that most patients eventually develop acquired resistance after ...
Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9: 212. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels...
Here, we contrast the mechanisms initiating and sustaining adaptive immune responses during primary infection with the immune pathways that are pre-existing and reactivated during secondary dengue. We also discuss new developments in our understanding of the contributions of CD4+ T cells, CD8+ T ...
Acquired resistance evolves as a therapy-directed and adaptive selection of alterations. • Intrinsic and acquired resistance alterations should be pursued on a different panel of biomarkers. Abstract The effectiveness of targeted therapies is currently limited, as almost all patients eventually acquire ...
While immunomodulatory drugs have selective actions in the adaptive immune system mediated by the regulatory subsets of the CD4+ T lymphocytes, immunosuppressive drugs like corticosteroids affect several parts of the immune response affecting both the innate and adaptive immune system resulting in a ‘...
Therapeutic advancements based on immuno-oncology combinations have revolutionized the management of patients with renal cell carcinoma. However, patients
Immune checkpoint inhibitors (ICIs) redefined the therapeutics of non-small cell lung cancer (NSCLC), leading to significant survival benefits and unprecedented durable responses. However, the majority of the patients develop resistance to ICIs, either primary or acquired. Establishing a definition of ...